Am. J. Respir. Crit. Care Med., Volume 156, Number 2, August 1997, 382-388

Endothelin-1-induced Bronchoconstriction in Asthma

GEORGE W. CHALMERS, STUART A. LITTLE, KANTILAL R. PATEL, and NEIL C. THOMSON

Department of Respiratory Medicine, West Glasgow Hospitals University NHS Trust, Glasgow, United Kingdom

Endothelin-1 (ET-1) has been indirectly implicated in the pathophysiology of asthma, and it is a potent bronchoconstrictor both in vitro and by inhalation in animal models in vivo. We examined the effect of inhaled ET-1 on airway tone in comparison with methacholine in eight asthmatics and five healthy volunteers in a double-blind randomized fashion. After a screening methacholine challenge each asthmatic had two ET-1 (doubling dose range, 0.96 to 15.36 nmol) and one methacholine (doubling dose range, 0.33 to 21.0 µmol) challenge, and normal subjects had a single ET-1 challenge. Inhalations were delivered using a dosimeter, and lung function measurements were made using constant-volume body plethysmography, with end points being a 35% fall in specific airway conductance (SGaw) and a 15% fall in FEV₁. Samples for plasma ET-1 were taken before and after the inhalations, and pulse, blood pressure and oxygen saturation were monitored throughout the inhalations. All the asthmatic subjects displayed rapid-onset (< 5 min) dose-dependent bronchconstriction to ET-1 across the dose range used, with mean (range) ET-1 PC₃₅SGaw values of 5.15 (1.4 to 13.9) nmol, and 4.3 (1.2 to 8.3) nmol for the two ET-1 inhalations, and 0.42 (0.2 to 0.7) µmol for methacholine. Albuterol completely and rapidly reversed ET-1-induced bronchoconstriction, and in two patients not given albuterol, bronchoconstriction lasted 60 to 90 min. No significant bronchoconstriction was observed in any of the healthy volunteers across the ET-1 dose range used (mean PC₃₅SGaw > 15.36 nmol). Oxygen saturation did not alter in either group, and plasma ET-1 did not change after ET-1 inhalation. Noninvasive blood pressure measurements revealed a fall in systolic blood pressure in normal subjects, with no change in asthmatics. Endothelin-1 is a potent bronchoconstrictor in asthma, with a bronchoconstrictor potency around 100 times that of methacholine in asthma. Asthmatics exhibit bronchial hyperractivity to ET-1, and inhaled ET-1 can safely be given to asthmatics and normal subjects in the nebulized dose range 0.96 to 15.36 nmol.

This article has been cited by other articles:

				R. McWhinnie, D. V. Pechkovsky, D. Zhou, D. Lane, A. J. Halayko, D. A. Knight, and T. R. Bai Endothelin-1 induces hypertrophy and inhibits apoptosis in human airway smooth muscle cells Am J Physiol Lung Cell Mol Physiol, January 1, 2007; 292(1): L278 - L286. [Abstract] [Full Text] [PDF]

				B. J. Canning Reflex regulation of airway smooth muscle tone J Appl Physiol, September 1, 2006; 101(3): 971 - 985. [Abstract] [Full Text] [PDF]

				H. Sylvin, E. Weitzberg, and K. Alving Endothelin-induced vascular and bronchial effects in pig airways: role in acute allergic responses J Appl Physiol, November 1, 2002; 93(5): 1608 - 1615. [Abstract] [Full Text] [PDF]

				P. J. Henry, T. S. Mann, A. C. D'Aprile, G. J. Self, and R. G. Goldie An endothelin receptor antagonist, SB-217242, inhibits airway hyperresponsiveness in allergic mice Am J Physiol Lung Cell Mol Physiol, November 1, 2002; 283(5): L1072 - L1078. [Abstract] [Full Text] [PDF]

				N. H.S. Kim and L. J. Rubin Endothelin in Health and Disease: Endothelin Receptor Antagonists in the Management of Pulmonary Artery Hypertension Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2002; 7(1): 9 - 19. [Abstract] [PDF]

				F. Finsnes, T. Lyberg, G. Christensen, and O. H. Skjonsberg Effect of endothelin antagonism on the production of cytokines in eosinophilic airway inflammation Am J Physiol Lung Cell Mol Physiol, April 1, 2001; 280(4): L659 - L665. [Abstract] [Full Text] [PDF]

				M Roland, A Bhowmik, R J Sapsford, T A R Seemungal, D J Jeffries, T D Warner, and J A Wedzicha Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease Thorax, January 1, 2001; 56(1): 30 - 35. [Abstract] [Full Text]

				G. W. Chalmers, E. A. Millar, S. A. Little, M. C. Shepherd, and N. C. Thomson Effect of Infused Angiotensin II on the Bronchoconstrictor Activity of Inhaled Endothelin-1 in Asthma Chest, February 1, 1999; 115(2): 352 - 356. [Abstract] [Full Text] [PDF]

				P. J. Barnes, K. F. Chung, and C. P. Page Inflammatory Mediators of Asthma: An Update Pharmacol. Rev., December 1, 1998; 50(4): 515 - 596. [Abstract] [Full Text] [PDF]

				F. FINSNES, G. CHRISTENSEN, T. LYBERG, O. M. SEJERSTED, and O. H. SKJONSBERG Increased Synthesis and Release of Endothelin-1 during the Initial Phase of Airway Inflammation Am. J. Respir. Crit. Care Med., November 1, 1998; 158(5): 1600 - 1606. [Abstract] [Full Text] [PDF]

				P. J. BARNES Pharmacology of Airway Smooth Muscle Am. J. Respir. Crit. Care Med., November 1, 1998; 158(2007): S123 - S132. [Abstract] [Full Text] [PDF]